Summary
Succinobucol (AGI-1067) is a novel compound believed to reduce inflammation in blood vessel walls. This article gives an overview of the findings from the Phase 3 randomized, double-blind Aggressive Reduction of Inflammation Stops Events [ARISE] study.
- Coronary Artery Disease Clinical Trials
- © 2007 MD Conference Express
Tools
Table of contents
Cited By...
- No citing articles found.